Please login to the form below

Not currently logged in
Email:
Password:

antidepressants

This page shows the latest antidepressants news and features for those working in and with pharma, biotech and healthcare.

Alkermes slumps as FDA turns down depression drug

Alkermes slumps as FDA turns down depression drug

Alkermes has been hit hard by the FDA’s rejection of antidepressant candidate ALKS 5461 - citing a lack of evidence that it was clinically effective. ... Despite the large number of approved agents, the majority of MDD patients treated with standard

Latest news

More from news
Approximately 9 fully matching, plus 247 partially matching documents found.

Latest Intelligence

  • Pharma deals during June 2014 Pharma deals during June 2014

    Pfizer is not the only major pharma in this position; also this month GSK settled US claims of irregular marketing activities in asthma and antidepressants at a reported $105m.

  • Interview: Beate Wieseler, IQWIG Interview: Beate Wieseler, IQWIG

    This was especially true in the “ landmark” case of Pfizer's antidepressant reboxetine, with IQWiG spending two years obtaining all the data it needed from Pfizer. “

  • Interview: Michel Goldman, Innovative Medicines Initiative Interview: Michel Goldman, Innovative Medicines Initiative

    antidepressants. "Another project, by the IMIDIA consortium on diabetes, has generated cell lines which reproduce the response of insulin-secreting cells in the pancreas, the beta cells, and these beta cell

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

Porterhouse Medical provides medical and scientific communication services to the pharmaceutical industry across the globe, with a focus on solutions...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics